Gluscan

Gluscan is a radiopharmaceutical that contains the active ingredient fludeoxyglucose (18F). It is supplied for intravenous administration, although specific strength and dosage form are not publicly disclosed. The product is marketed in the European Union and is prescribed by qualified healthcare professionals for diagnostic imaging. Fludeoxyglucose (18F) functions as a glucose analog that highlights metabolically active tissues during positron emission tomography (PET) scans in clinical practice.

Gluscan is indicated for several PET imaging applications that require visualization of cellular glucose metabolism.

- Detection, staging, and monitoring of malignant tumors in oncology. - Assessment of metabolic activity in lesions suspected of cancer. - Evaluation of treatment response in patients receiving chemotherapy, radiotherapy, or targeted therapy. - Investigation of unknown primary tumors when conventional imaging is inconclusive. - Differentiation of benign from malignant processes in certain neuroendocrine tumors.

Adverse reactions to Gluscan are generally related to the radiopharmaceutical nature of the product and the intravenous route of administration.

Common: - Transient flushing or warmth at the injection site. - Mild nausea or vomiting shortly after injection. - Brief headache or dizziness. - Temporary metallic taste in the mouth. - Low-grade fatigue lasting a few hours.

Serious: - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Significant radiation‑induced skin erythema at the injection site. - Severe hypotension or syncope.

Because Gluscan contains a radioactive tracer, specific precautions are required to ensure patient safety and accurate imaging results.

- Verify patient identity and confirm the indication before administration. - Ensure proper hydration and encourage fluid intake after injection to facilitate tracer clearance. - Assess for known hypersensitivity to fluorodeoxyglucose or other radiopharmaceuticals. - Avoid administration to pregnant or breastfeeding women unless the benefit outweighs potential risk. - Maintain appropriate radiation protection measures for staff and surrounding individuals. - Document the administered activity and time of injection accurately.

Gluscan may interact with other substances that affect glucose metabolism or radiation exposure, requiring attention to concurrent medications and procedures.

Avoid: - Concurrent use of high‑dose glucose or dextrose solutions that can competitively inhibit tracer uptake. - Administration of other radiopharmaceuticals within a short interval that could confound PET image interpretation.

Use with caution: - Antidiabetic medications (e.g., insulin, metformin) that alter blood glucose levels; blood glucose should be measured and controlled before the scan. - Recent chemotherapy or radiation therapy, which may affect tracer distribution. - Contrast agents used in CT imaging performed in the same session, as they may influence attenuation correction.